Abstract
Fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) are hydrolytic enzymes which degrade the endogenous cannabinoids (endocannabinoids) N-arachidonoylethanolamine (anandamide, AEA) and 2- arachidonoylglycerol (2-AG), respectively. Endocannabinoids are an important class of lipid messenger molecules that are produced on demand in response to elevated intracellular calcium levels. They recognize and activate the cannabinoid CB1 and CB2 receptors, the molecular targets for Δ9-tetrahydrocannabinol (Δ9-THC) in marijuana evoking several beneficial therapeutic effects. However, in vivo the cannabimimetic effects of AEA and 2-AG remain weak owing to their rapid inactivation by FAAH and MGL, respectively. The inactivation of FAAH and MGL by specific enzyme inhibitors increases the levels of AEA and 2-AG, respectively, producing therapeutic effects such as pain relief and depression of anxiety. A variety of chemically diverse FAAH and MGL inhibitors have been developed and synthesized recently. Thus, this article reviews the scientific literature of various FAAH and MGL inhibitors presented during the past ten years.
Keywords: Endocannabinoids, Fatty acid amide hydrolase, Monoglyceride lipase, Monoacylglycerol lipase, N-arachidonoylethanolamine, 2-Arachidonoylglycerol
Current Topics in Medicinal Chemistry
Title: Discovery and Development of Endocannabinoid-Hydrolyzing Enzyme Inhibitors
Volume: 10 Issue: 8
Author(s): Anna Minkkila, Susanna M. Saario and Tapio Nevalainen
Affiliation:
Keywords: Endocannabinoids, Fatty acid amide hydrolase, Monoglyceride lipase, Monoacylglycerol lipase, N-arachidonoylethanolamine, 2-Arachidonoylglycerol
Abstract: Fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) are hydrolytic enzymes which degrade the endogenous cannabinoids (endocannabinoids) N-arachidonoylethanolamine (anandamide, AEA) and 2- arachidonoylglycerol (2-AG), respectively. Endocannabinoids are an important class of lipid messenger molecules that are produced on demand in response to elevated intracellular calcium levels. They recognize and activate the cannabinoid CB1 and CB2 receptors, the molecular targets for Δ9-tetrahydrocannabinol (Δ9-THC) in marijuana evoking several beneficial therapeutic effects. However, in vivo the cannabimimetic effects of AEA and 2-AG remain weak owing to their rapid inactivation by FAAH and MGL, respectively. The inactivation of FAAH and MGL by specific enzyme inhibitors increases the levels of AEA and 2-AG, respectively, producing therapeutic effects such as pain relief and depression of anxiety. A variety of chemically diverse FAAH and MGL inhibitors have been developed and synthesized recently. Thus, this article reviews the scientific literature of various FAAH and MGL inhibitors presented during the past ten years.
Export Options
About this article
Cite this article as:
Minkkila Anna, M. Saario Susanna and Nevalainen Tapio, Discovery and Development of Endocannabinoid-Hydrolyzing Enzyme Inhibitors, Current Topics in Medicinal Chemistry 2010; 10 (8) . https://dx.doi.org/10.2174/156802610791164238
DOI https://dx.doi.org/10.2174/156802610791164238 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Management of Dyslipidaemia for the Prevention of Stroke: Clinical
Practice Recommendations from the Lipid Association of India
Current Vascular Pharmacology WITHDRAWN: Current Trends in the Detection of Biological Proteins and Immunological Assays using Graphene Quantum Dots
Current Analytical Chemistry Application of Nanotechnology in Miniaturized Systems and its Use for Advanced Analytics and Diagnostics – an Updated Review
Recent Patents on Food, Nutrition & Agriculture Synthesis, Characterization, Applications, and Toxicity of Green Synthesized Nanoparticles
Current Pharmaceutical Biotechnology The Study on the Fingerprint and Qualitative Analysis of Characteristic Volatile Constituens in Xihuang Pill by GC/GC-MS
Current Analytical Chemistry Current Strategies for the Treatment of Ulcerative Colitis
Recent Patents on Inflammation & Allergy Drug Discovery Biological Activities of Natural and Engineered Cyclotides, a Novel Molecular Scaffold for Peptide-Based Therapeutics
Current Molecular Pharmacology Detection of Squamous Cell Carcinoma Antigen with Micro- and Nanogap Interdigitated Electrodes and Gold Nanoparticles
Micro and Nanosystems The Colostrum Proteome, Ruminant Nutrition and Immunity: A Review
Current Protein & Peptide Science Microwave-Assisted Synthesis of N-Alkylated Bibenzoimidazolyl Derivatives: Antimicrobial Studies
Letters in Drug Design & Discovery Review of Characteristics, Pharmacology, Determination and Pharmacokinetics of Rhaponticin
Mini-Reviews in Organic Chemistry The Next Step in Voice Assessment: High-Speed Digital Endoscopy and Objective Evaluation
Current Bioinformatics Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design Combating Malaria with Plant Molecules: A Brief Update
Current Medicinal Chemistry Resveratrol and Ischemic Preconditioning in the Brain
Current Medicinal Chemistry Propitious Profile of Peppery Piperine
Current Molecular Pharmacology Synthesis and in vitro Anti-tumor Activity of Some New Sebacoyl Chloride Based Heterocycles
Current Organic Synthesis <i>Ralstonia Mannitolilytica</i>, an Unusual Pathogen in the Neonatal Intensive Care Unit: A Case of Neonatal Sepsis and Literature Review
Infectious Disorders - Drug Targets Folate Receptor Targeted Liposomes Encapsulating Anti-Cancer Drugs
Current Pharmaceutical Biotechnology Herbal Resources to Combat a Progressive & Degenerative Nervous System Disorder- Parkinson’s Disease
Current Drug Targets